SCARNA23: A Potential Drug Target and Biomarker (G677773)

Target Name: SCARNA23

NCBI ID: G677773

SCARNA23

Other Name(s): Small Cajal body-specific RNA 23 | ACA12 | small Cajal body-specific RNA 23

SCARNA23: A Potential Drug Target and Biomarker

Small Cajal body-specific RNA 23 (SCARNA23) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. SCARNA23 is a key regulator of gene expression in the Cajal-Retzius system, a protein complex that plays a crucial role in the regulation of neural circuits in the brain. The Cajal-Retzius system is composed of three subunits: CRISPR-Cas9, Prm1 and Prm2, which work together to ensure the accuracy and consistency of gene expression profiles in neural tissues.

Recent studies have identified SCARNA23 as a key regulator of gene expression in various neural tissues, including the brain. By using RNA sequencing and other techniques, researchers have shown that SCARNA23 plays a critical role in the regulation of neuronal excitability, synaptic plasticity, and neuronal communication.

SCARNA23 is also a potential biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. The exact mechanisms by which SCARNA23 contributes to these disorders is not yet fully understood, but its involvement in their development and progression is an attractive area of research.

One of the key challenges in studying SCARNA23 is its expression and function in neural tissues, as the molecule is highly expressed in a variety of tissues and cells, making it difficult to isolate and study. However, researchers have been able to use techniques such as RNA interference and CRISPR-Cas9 to manipulate SCARNA23 expression and identify its specific role in neural development and function.

In addition to its potential drug target and biomarker properties, SCARNA23 also has interesting structural and computational properties that are worth exploring. The molecule is a small non-coding RNA molecule that has a length of approximately 23 nucleotides. It is composed of a single exon that is expressed in the brain, and it has been shown to be highly expressed in various neural tissues.

The structure of SCARNA23 is also of interest, as it has been shown to have a unique fold that is distinct from other non-coding RNAs. This fold is thought to play a critical role in the regulation of gene expression, and future studies will be interested in understanding the mechanisms by which SCARNA23 uses this fold to control gene expression.

In conclusion, SCARNA23 is a promising drug target and biomarker that has the potential to revolutionize our understanding of neurological and psychiatric disorders. Further studies will be needed to fully understand its mechanisms of action and its potential as a therapeutic intervention.

Protein Name: Small Cajal Body-specific RNA 23

The "SCARNA23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCARNA23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets